Anamorelin Effectively Targets Cachexia in Patients with Advanced Non Small Cell Lung Cancer

Patients with some cancers, such as pancreatic and especially non small cell lung cancer- the most common cancer killer frequently waste away not attributable to chemotherapy but various factors tumors produce- killing appetite and so much more metabolically and psychologically. There are some treatments  to try and stimulate appetite but they are not that effective or can be not worth it and in essence do not go after the mechanism of this cachexia, as it called. Patients who waste away have shorter remissions , less responses and shorter survival and is not due to a mere lack of effort on their part, this breakthrough study shows the utility of another drug

Treatment with anamorelin, a highly selective ghrelin receptor agonist, resulted in significant increases in lean body mass and body weight in patients with advanced non–small cell lung cancer (NSCLC) and cachexia compared with placebo, according to the results of the ROMANA 1 and 2 trials presented during the Patient and Survivor Care Oral Abstract Session on Monday, June 1

One Response to Anamorelin Effectively Targets Cachexia in Patients with Advanced Non Small Cell Lung Cancer

  1. drkevinryan says:

    So sorry to hear you feel this way. You are, with all due respect, woefully misinformed. There is no harm to read solid facts from the other side- get the book. There is NO CORROBORATED DATA OR TRIAL CORRRECTLY DOEN that shows what you assert- none, sorry

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.